Let’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu

FJ ⭐️⭐️+⭐️· @pistoto2017 · X·2026-10-25 01:33· 12 小时前评分70

正文 · 原文

Let’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu @drshieldsmd @Tony_Calles @LuisPaz_Ares @lungoncdoc @Annechiangmd @LealTiciana @latina @MartinReck2

218 浏览 · 4 赞 · 1 转发 · 2 回复

会议摘要

LBA3按 Presidential Symposium I 对上

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

帖内回复

FJ ⭐️⭐️+⭐️@pistoto2017
#sclc #esmo26 #tarlatamab
Cosas De Bolsa@BolsaCosas
@pistoto2017 Que listos son los de #Amgen siempre modificando los ensayos a su favor, claro, pero tan descarado...tan descarado. Es que es increíble que en un estudio tan importante hagan éstas cosas

来源：FJ ⭐️⭐️+⭐️ · x.com